Aldeyra Therapeutics (ALDX) Prepaid Assets (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Prepaid Assets of $1.3 million for Q1 2026, down 27.02% on a QoQ basis from $1.7 million in Q4 2025, and down 52.39% year-over-year from $2.7 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Prepaid Assets (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Prepaid Assets history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- Quarterly Prepaid Assets fell 52.39% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 52.39% YoY) and the FY2025 annual result came in at $1.7 million, up 326.92% from the prior year.
- Prepaid Assets was $1.3 million for Q1 2026 at Aldeyra Therapeutics, down from $1.7 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $7.8 million in Q1 2024 and bottomed at $23685.0 in Q1 2023.
- A 5-year average of $3.5 million and a median of $4.0 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets tumbled 99.57% — and 2024, when it soared 32868.53%.
- Aldeyra Therapeutics' Prepaid Assets stood at $6.7 million in 2022, then decreased by 25.81% to $5.0 million in 2023, then plunged by 91.82% to $408091.0 in 2024, then soared by 326.92% to $1.7 million in 2025, then retreated by 27.02% to $1.3 million in 2026.
- Business Quant data shows ALDX's Prepaid Assets at $1.3 million in Q1 2026, $1.7 million in Q4 2025, and $721650.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 721,650.00 |
| Jun 30, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.67 Mn |
| Dec 31, 2024 | 408,091.00 |
| Sep 30, 2024 | 3.98 Mn |
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Mar 31, 2023 | 23,685.00 |
| Dec 31, 2022 | 6.72 Mn |
| Sep 30, 2022 | 4.15 Mn |
| Jun 30, 2022 | 4.05 Mn |
| Mar 31, 2022 | 5.49 Mn |
| Dec 31, 2021 | 28,770.00 |
| Sep 30, 2021 | 5.40 Mn |
| Jun 30, 2021 | 6.52 Mn |
| Mar 31, 2021 | 8.63 Mn |
| Dec 31, 2020 | 5.20 Mn |